Richard Rosenquist Brandell has been honored as the Pharmaceutical Profile of the Year 2025 for his significant contributions to establishing a national infrastructure for precision medicine in Sweden. The award is presented by Läkemedelsmarknaden in collaboration with Dagens Medicin and Dagens Industri. This recognition highlights Brandell’s commitment to enhancing healthcare through innovative approaches that involve all stakeholders, including patients.
A Vision for Precision Medicine
As a senior consultant in clinical genetics at Karolinska University Hospital and a professor at the Department of Molecular Medicine and Surgery at Karolinska Institutet, Brandell has played a pivotal role in the development of Genomic Medicine Sweden (GMS). Since its inception in 2018, GMS has focused on creating a comprehensive infrastructure aimed at improving diagnostics, personalizing treatment options, and advancing research in precision medicine.
The Pharmaceutical Profile of the Year award recognizes individuals who foster collaboration between healthcare, industry, research, and patients. Brandell’s leadership at GMS exemplifies this mission. “The strength of GMS lies in the very close collaboration between all stakeholders, which has made it possible for us to offer precision diagnostics nationwide,” Brandell stated. His efforts have bridged gaps between various sectors, ensuring that patient needs are at the forefront of healthcare development.
Commitment to Collaboration
Brandell expressed his gratitude upon receiving the award on December 4, 2025, stating, “I feel deeply honored as a clinical geneticist to receive this award; it truly came as a surprise.” His dedication has not only propelled advancements in precision medicine but has also involved patients directly in the development process, ensuring their voices and experiences shape treatment options.
The recognition of Brandell’s work aligns with a growing emphasis on personalized healthcare solutions, where treatments are tailored to individual genetic profiles. This approach aims to enhance treatment efficacy and minimize adverse effects, ultimately improving patient outcomes.
As the landscape of healthcare continues to evolve, the contributions of leaders like Richard Rosenquist Brandell are crucial. His work through GMS serves as a model for integrating precision medicine into standard healthcare practices, paving the way for future innovations in the field.
